HC Wainwright & Co. Reiterates Buy on Faeth Therapeutics, Maintains $60 Price Target
Faeth Therapeutics, Inc.
Faeth Therapeutics, Inc. FTH | 0.00 |
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Faeth Therapeutics (NASDAQ:
FTH) with a Buy and maintains $60 price target.
